Alembic: The financial results for the period ended September 30, 2026

What happened

Alembic (ALEMBICLTD) filed a disclosure with the exchanges on 6 November 2026 at 04:45 PM titled "The financial results for the period ended September 30, 2026".

Company snapshot

Alembic is a small-cap company, with a market value of about ₹2,432 crore.

The stock last traded at ₹94.71, against a 52-week range of ₹70.46–₹117.7 (19.6% below the high).

Before this filing the shares had moved −9.3% over the month and +9.3% over three months. Average daily turnover over the last 20 sessions was about ₹4.32 crore.

Promoters held 70.88% at the end of Q1 FY27. Foreign institutions owned 1.25% and domestic institutions 0.05%.

What history shows

This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.

Market-wide, 10,840 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.
• 6 November 2026: Board meeting — Financial Results/Other business matters.

In the news

Recent coverage elsewhere (links open the original publisher):

• Alembic Pharma Q2 net surges 81% to ₹335 crore — The Hindu, 5 Nov 2026
• Alembic Pharma Shares Rise After USFDA Nod for Eye Drops — Equitypandit, 5 Nov 2026
• Alembic Pharma Q2 net profit climbs 81% to ₹335 crore on US branded pivot — pharma.economictimes.indiatimes.com, 5 Nov 2026
• Alembic Pharma's Stock Hits Upper Circuit After Q2 Profit Zooms Over 81% — NDTV Profit, 4 Nov 2026
• Alembic Pharma shares hit 20% upper circuit after 81% YoY rise in Q2 PAT — Business Standard, 4 Nov 2026

Source

• Exchange filing (PDF)